Vemurafenib-话题@MedSci

#Vemurafenib#

10篇内容 | 1213人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1663185, encodeId=2ebf1663185db, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, objectTitle=Lancet Oncol：阿特珠单抗+Cobimetinib+Vemurafenib治疗CNS转移的黑色素瘤, objectType=article, longId=735293, objectId=8390e3529363, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8390e3529363, replyNumber=0, likeNumber=95, createdTime=2022-12-05, rootId=0, userName=ms1292405679162969, userId=29c625536559, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8390e3529363, moduleTitle=Lancet Oncol：阿特珠单抗+Cobimetinib+Vemurafenib治疗CNS转移的黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8390e3529363)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663183, encodeId=7af2166318345, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, objectTitle=Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果, objectType=article, longId=213315, objectId=46ab21331526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46ab21331526, replyNumber=0, likeNumber=68, createdTime=2021-08-25, rootId=0, userName=ms1292405679162969, userId=29c625536559, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46ab21331526, moduleTitle=Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46ab21331526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663184, encodeId=a9941663184e3, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, objectTitle=Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤, objectType=article, longId=214664, objectId=c24a214664ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c24a214664ad, replyNumber=0, likeNumber=84, createdTime=2021-11-26, rootId=0, userName=ms1292405679162969, userId=29c625536559, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c24a214664ad, moduleTitle=Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c24a214664ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663182, encodeId=e5701663182f8, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, objectTitle=Lancet：Atezolizumab-Vemurafenib-Cobimetinib一线治疗晚期BRAF V600突变阳性黑色素瘤, objectType=article, longId=195816, objectId=65141958168d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65141958168d, replyNumber=0, likeNumber=78, createdTime=2020-10-02, rootId=0, userName=ms1292405679162969, userId=29c625536559, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65141958168d, moduleTitle=Lancet：Atezolizumab-Vemurafenib-Cobimetinib一线治疗晚期BRAF V600突变阳性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65141958168d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663181, encodeId=6f9316631818f, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, objectTitle=CLIN CANCER RES：周细胞调节甲状腺癌Vemurafenib和Sorafenib治疗耐药, objectType=article, longId=156246, objectId=945a15624619, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=945a15624619, replyNumber=0, likeNumber=89, createdTime=2019-05-19, rootId=0, userName=ms1292405679162969, userId=29c625536559, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=945a15624619, moduleTitle=CLIN CANCER RES：周细胞调节甲状腺癌Vemurafenib和Sorafenib治疗耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=945a15624619)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663180, encodeId=9c3c166318083, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, objectTitle=2016NICE技术评估指南：cobimetinib联合vemurafenib治疗不能手术切除或转移性BRAF V600突变阳性黑色素瘤（TA414）发布, objectType=article, longId=81114, objectId=c6088111417, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6088111417, replyNumber=0, likeNumber=78, createdTime=2017-07-19, rootId=0, userName=ms1292405679162969, userId=29c625536559, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6088111417, moduleTitle=2016NICE技术评估指南：cobimetinib联合vemurafenib治疗不能手术切除或转移性BRAF V600突变阳性黑色素瘤（TA414）发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6088111417)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663179, encodeId=c99416631e916, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, objectTitle=Lancet Oncol：治疗黑色素瘤的一线药物cobimetinib+vemurafenib, objectType=article, longId=76325, objectId=ab52e63254e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab52e63254e, replyNumber=0, likeNumber=77, createdTime=2017-02-01, rootId=0, userName=ms1292405679162969, userId=29c625536559, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab52e63254e, moduleTitle=Lancet Oncol：治疗黑色素瘤的一线药物cobimetinib+vemurafenib, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab52e63254e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663178, encodeId=028c16631e824, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, objectTitle=NEJM：短期内治疗复发性或难治性多毛细胞白血病，vemurafenib很有效, objectType=article, longId=56056, objectId=8dbf5605679, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dbf5605679, replyNumber=0, likeNumber=75, createdTime=2015-11-12, rootId=0, userName=ms1292405679162969, userId=29c625536559, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dbf5605679, moduleTitle=NEJM：短期内治疗复发性或难治性多毛细胞白血病，vemurafenib很有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dbf5605679)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663177, encodeId=722116631e7d5, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, objectTitle=NEJM：Vemurafenib在多种BRAF V600突变的黑色素癌的作用, objectType=article, longId=55314, objectId=b80155314e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b80155314e4, replyNumber=0, likeNumber=87, createdTime=2016-08-08, rootId=0, userName=ms1292405679162969, userId=29c625536559, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b80155314e4, moduleTitle=NEJM：Vemurafenib在多种BRAF V600突变的黑色素癌的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b80155314e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663176, encodeId=4b7016631e62c, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, objectTitle=Lancet Oncol：Vemurafenib治疗黑色素瘤安全有效, objectType=article, longId=31254, objectId=f93a31254a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f93a31254a0, replyNumber=0, likeNumber=88, createdTime=2014-11-14, rootId=0, userName=ms1292405679162969, userId=29c625536559, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f93a31254a0, moduleTitle=Lancet Oncol：Vemurafenib治疗黑色素瘤安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f93a31254a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Vemurafenib

2020-05-29

ms1292405679162969 (审核中...)

前往app查看评论内容

#Vemurafenib#

Lancet Oncol：阿特珠单抗+Cobimetinib+Vemurafenib治疗CNS转移的黑色素瘤

2022-12-05

ms1292405679162969 (审核中...)

前往app查看评论内容

#Vemurafenib#

Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果

2021-08-25

ms1292405679162969 (审核中...)

前往app查看评论内容

#Vemurafenib#

Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤

2021-11-26

ms1292405679162969 (审核中...)

前往app查看评论内容

#Vemurafenib#

Lancet：Atezolizumab-Vemurafenib-Cobimetinib一线治疗晚期BRAF V600突变阳性黑色素瘤

2020-10-02

ms1292405679162969 (审核中...)

前往app查看评论内容

#Vemurafenib#

CLIN CANCER RES：周细胞调节甲状腺癌Vemurafenib和Sorafenib治疗耐药

2019-05-19

ms1292405679162969 (审核中...)

前往app查看评论内容

#Vemurafenib#

2016NICE技术评估指南：cobimetinib联合vemurafenib治疗不能手术切除或转移性BRAF V600突变阳性黑色素瘤（TA414）发布

2017-07-19

ms1292405679162969 (审核中...)

前往app查看评论内容

#Vemurafenib#

Lancet Oncol：治疗黑色素瘤的一线药物cobimetinib+vemurafenib

2017-02-01

ms1292405679162969 (审核中...)

前往app查看评论内容

#Vemurafenib#

NEJM：短期内治疗复发性或难治性多毛细胞白血病，vemurafenib很有效

2015-11-12

ms1292405679162969 (审核中...)

前往app查看评论内容

#Vemurafenib#

NEJM：Vemurafenib在多种BRAF V600突变的黑色素癌的作用

2016-08-08

ms1292405679162969 (审核中...)

前往app查看评论内容

#Vemurafenib#

Lancet Oncol：Vemurafenib治疗黑色素瘤安全有效

2014-11-14

科室
- - 订阅+
  - 更多科室
工具
服务